Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Medicover

Medicover

Medicover is an international provider of healthcare and diagnostic services. Medicover's business is divided into two segments: Healthcare Services (69% of 2025 sales) and Diagnostic Services (31%). The company focuses on providing a wide range of high-quality healthcare solutions, from hospital care and specialist services to diagnostic testing and fitness centres. Key markets include Poland (53% of sales), Germany (15%), Romania (13%) and India (10%), as of Q2'26.

Sustainability information

Key risks include competition from local players, executing M&A transactions and integrating acquired businesses. Regulatory changes, particularly in healthcare reimbursement policies, pose additional challenges. Other risks include the operational scale-up of certain tests and dependence on skilled healthcare professionals in competitive labour markets.

EURm 2025 2026e 2027e
Sales 2378,1 2467,09 2611,43
Sales growth (%) 13,7 3,7 5,9
EBITDA 371 406 466
EBITDA margin (%) 15,6 16,5 17,8
EBIT adj. 156 190 229
EBIT adj. margin (%) 6,5 7,7 8,8
Pretax profit 98 130 198
EPS 0,51 0,64 0,94
EPS growth (%) N/A 24,6 47,7
EPS adj. 0,58 0,71 1,09
Dividend per share 0,2 0,23 0,28
EV/EBITDA (x) 13,6 10,3 8,8
EV/EBIT adj. (x) 32,4 22 18
P/E (x) 47,36 38 25,73
P/E adj. (x) 42 34,4 22,3
EV/sales (x) 2,12 1,7 1,57
FCF yield (%) 0,4 25,2 7
Le. adj. FCF yld. (%) -1,9 22,9 4,7
Dividend yield (%) 0,8 0,9 1,1
Net IB debt/EBITDA (x) 3,6 1,2 0,8
Le. adj. ND/EBITDA (x) 2,9 0,1 -0,2
EURm 2025 2026e 2027e
Sales 2378,1 2467,09 2611,43
COGS -1827 -2019 -2420
Gross profit 551 448 191
Other operating items -180 -42 274
EBITDA 371 406 466
Depreciation and amortisation -296 -286 -269
Depreciation on leased assets -96 -100 -94
EBITA 170,6 204,02 258,5
Operating EO items 0 0 0
Impairment and amortisation charges -15 -14 -30
EBIT 155,7 190,32 228,5
Net financial items -59 -60 -31
Pretax profit 98 130 198
Tax -26 -35 -54
Net profit 73 95 144
Minority interest 5 2 0
Net profit discontinued 0 0 0
Net profit to shareholders 78 97 144
EPS 0,51 0,64 0,94
EPS adj. 0,58 0,71 1,09
Total extraordinary items after tax 1 0 0
Leasing payments -96 -100 -94
Tax rate (%) 26,1 26,9 27,3
Gross margin (%) 23,2 18,2 7,3
EBITDA margin (%) 15,6 16,5 17,8
EBITA margin (%) 7,2 8,3 9,9
EBIT margin (%) 6,5 7,7 8,8
Pre-tax margin (%) 4,1 5,3 7,6
Net margin (%) 3,1 3,9 5,5
Sales growth (%) 13,7 3,7 5,9
EBITDA growth (%) 30,2 9,5 14,5
EBITA growth (%) 62,9 19,6 26,7
EBIT growth (%) N/A 22,2 20,1
Net profit growth (%) 397,9 30,9 50,9
EPS growth (%) N/A 24,6 47,7
Profitability N/A N/A N/A
Year N/A N/A N/A
ROE (%) 15,5 11,2 11,5
ROE adj. (%) 18,3 12,8 13,9
ROCE (%) 8,5 8,4 8,7
ROCE adj. (%) 9,2 9 9,9
ROIC (%) 7,2 8,4 11,1
ROIC adj. (%) 7,2 8,4 11,1
Adj. earnings numbers N/A N/A N/A
EBITDA adj. 371 406 466
EBITDA adj. margin (%) 15,6 16,5 17,8
EBITDA lease adj. 275 307 372
EBITDA lease adj. margin (%) 11,6 12,4 14,2
EBITA adj. 171 204 259
EBITA adj. margin (%) 7,2 8,3 9,9
EBIT adj. 156 190 229
EBIT adj. margin (%) 6,5 7,7 8,8
Pretax profit Adj. 112 144 228
Net profit Adj. 86 109 174
Net profit to shareholders adj. 91 111 174
Net adj. margin (%) 3,6 4,4 6,6
EURm 2025 2026e 2027e
EBITDA 371 406 466
Goodwill 655 612 612
Net financial items -59 -60 -31
Other intangible assets 158 164 178
Paid tax -26 -35 -54
Tangible fixed assets 528 452 473
Non-cash items 50 40 31
Right-of-use asset 521 377 370
Cash flow before change in WC 337 351 412
Other Fixed Assets All 62 67 67
Change in working capital 7 -22 -5
Fixed assets 1924 1673 1701
Operating cash flow 344 330 407
Inventories 67 76 81
Capex tangible fixed assets -47 -38 -44
Receivables 341 318 339
Capex intangible fixed assets -110 -89 -102
Other current assets 6 5 5
Acquisitions and Disposals -173 729 0
Cash and liquid assets 83 862 970
Free cash flow 14 932 260
Total assets 2421 2934 3097
Dividend paid -23 -31 -35
Shareholders equity 533 1198 1307
Share issues and buybacks -8 -4 0
Minority 12 6 6
Leasing liability amortisation -85 -87 -87
Total equity 545 1204 1313
Other changes in net debt -71 81 -63
Long-term debt 621 389 389
Pension debt 0 0 0
Convertible debt 0 0 0
Leasing liability 559 448 480
Total other long-term liabilities 73 57 57
Short-term debt 260 510 510
Accounts payable 311 269 287
Other current liabilities 52 57 61
Total liabilities and equity 2421 2934 3097
Net IB debt 1342 468 393
Net IB debt excl. pension debt 1342 468 393
Net IB debt excl. leasing 783 20 -87
Capital employed 1985 2551 2692
Capital invested 1887 1672 1706
Working capital 51 73 78
Market cap. diluted (m) 3670 3695 3695
Net IB debt adj. 1357 485 409
Market value of minority 12 6 6
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity N/A N/A N/A
EV 5040 4185 4110
Total assets turnover (%) 104,3 92,1 86,6
Working capital/sales (%) 2,3 2,5 2,9
Year N/A N/A N/A
Financial risk and debt service N/A N/A N/A
Net debt/equity (%) 246,3 38,9 29,9
Net debt / market cap (%) 36,6 12,7 10,6
Equity ratio (%) 22,5 41 42,4
Net IB debt adj. / equity (%) 249,1 40,3 31,2
Current ratio 0,8 1,51 1,63
EBITDA/net interest 6,3 6,8 15
Net IB debt/EBITDA (x) 3,6 1,2 0,8
Net IB debt/EBITDA lease adj. (x) 2,9 0,1 -0,2
Interest coverage 2,9 3,4 8,3
EURm 2025 2026e 2027e
Shares outstanding adj. 151 152 152
Diluted shares adj. 151 152 152
EPS 0,51 0,64 0,94
Dividend per share 0,2 0,23 0,28
EPS adj. 0,58 0,71 1,09
BVPS 3,53 7,88 8,6
BVPS adj. -1,86 2,77 3,4
Net IB debt/share 8,99 3,19 2,69
Share price 270 270 270
Market cap. (m) 3670 3695 3695
P/E (x) 47,36 38 25,73
EV/sales (x) 2,12 1,7 1,57
EV/EBITDA (x) 13,6 10,3 8,8
EV/EBITA (x) 29,5 20,5 15,9
EV/EBIT (x) 32,4 22 18
Dividend yield (%) 0,8 0,9 1,1
FCF yield (%) 0,4 25,2 7
Le. adj. FCF yld. (%) -1,9 22,9 4,7
P/BVPS (x) 6,89 3,08 2,83
P/BVPS adj. (x) -30,06 6,31 5,32
P/E adj. (x) 42 34,4 22,3
EV/EBITDA adj. (x) 13,6 10,3 8,8
EV/EBITA adj. (x) 29,5 20,5 15,9
EV/EBIT adj. (x) 32,4 22 18
EV/CE (x) 2,5 1,6 1,5
Year N/A N/A N/A
Investment ratios N/A N/A N/A
Capex/sales (%) -6,6 -5,1 -5,6
Capex/depreciation 0,8 0,7 0,8
Capex tangibles / tangible fixed assets 8,9 8,4 9,3
Capex intangibles / definite intangibles N/A N/A N/A
Depreciation on intang / def. intang N/A N/A N/A
Depreciation on tangibles / tangibles 37,95 41,34 36,96

Equity research

Read earlier research

Media

Medicover - Company presentation with CEO John Stubbington

Main shareholders -

Main shareholders Share capital % Voting shares % Verified
Celox Holding 30.7 % 56.0 % 28 Sep 2026
NG Invest Beta AB 6.0 % 10.5 % 28 Sep 2026
Fredrik Stenmo 4.3 % 7.6 % 12 Feb 2026
Patrik af Jochnick 2.6 % 4.6 % 28 Sep 2026
Anna af Jochnick 2.5 % 4.6 % 28 Sep 2026
Peder af Jochnick 2.5 % 4.5 % 31 Dec 2025
Fjärde AP-fonden 8.5 % 1.6 % 28 Sep 2026
AMF Pension & Fonder 2.9 % 0.5 % 30 Sep 2026
Swedbank Robur Fonder 2.7 % 0.5 % 30 Sep 2026
Vanguard 1.5 % 0.3 % 30 Sep 2026
Source: Holdings by Modular Finance AB